Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord blood is a biologic product containing hematopoietic stem and progenitor cells (HSPCs) collected from the placenta and umbilical cord following childbirth. It is used as a source of stem cells for hematopoietic stem cell transplantation (HSCT) in patients with hematological malignancies, bone marrow failure syndromes, and certain genetic disorders. The primary therapeutic mechanism involves the reconstitution of the recipient's hematopoietic and immune systems following myeloablative or non-myeloablative conditioning. Cord blood is particularly valuable as an alternative to bone marrow or peripheral blood stem cells due to its lower requirement for HLA matching, although it is often associated with a lower total cell dose and slower engraftment. Several cord blood products are FDA-approved for hematopoietic reconstitution in patients with disorders affecting the hematopoietic system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord blood.